Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Jun 22

PMID 37349612

Authors

Leah Kim

Magdalena Coman

Lajos Pusztai

Tristen S Park

Affiliations

Soon will be listed here.

Abstract

Despite breast cancer being long thought to be "immunologically cold," within early, triple-negative breast cancer (TNBC), there has been exciting advances with the use of immune checkpoint modulation combined with neoadjuvant chemotherapy. We review the major trials that have investigated combination immunochemotherapy in the neoadjuvant setting, reviewing both the pathological complete response rates and the maturing data regarding event-free and overall survival. Strategies to deescalate adjuvant therapy in patients with preserving excellent clinical outcome, as well as exploration of combinatorial adjuvant therapies to improve outcome in those with extensive residual are the next-generation challenges. In addition to refinement of existing biomarkers, such as PD-L1, TILs, and tumor mutational burden (TMB), exploration of topics like the microbiome as both a biomarker and a therapeutic has shown promise in other cancer types, which motivates investigating these in breast cancer.

Citing Articles

Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

Seager R, Ko H, Pabla S, Senosain M, Kalinski P, Van Roey E J Pers Med. 2024; 14(5).

PMID: 38793063 PMC: 11122407. DOI: 10.3390/jpm14050481.

References

Waks A, Winer E . Breast Cancer Treatment: A Review. JAMA. 2019; 321(3):288-300. DOI: 10.1001/jama.2018.19323. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Pusztai L, Foldi J, Dhawan A, DiGiovanna M, Mamounas E . Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol. 2019; 20(7):e390-e396. DOI: 10.1016/S1470-2045(19)30158-5. View

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

Luen S, Virassamy B, Savas P, Salgado R, Loi S . The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016; 29:241-50. DOI: 10.1016/j.breast.2016.07.015. View

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

Loi S, Drubay D, Adams S, Pruneri G, Francis P, Lacroix-Triki M . Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019; 37(7):559-569. PMC: 7010425. DOI: 10.1200/JCO.18.01010. View

Mittendorf E, Philips A, Meric-Bernstam F, Qiao N, Wu Y, Harrington S . PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2(4):361-70. PMC: 4000553. DOI: 10.1158/2326-6066.CIR-13-0127. View

10.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View

11.

Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K . Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020; 26(12):2838-2848. PMC: 7299787. DOI: 10.1158/1078-0432.CCR-19-3492. View

12.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022; 386(6):556-567. DOI: 10.1056/NEJMoa2112651. View

13.

Mittendorf E, Zhang H, Barrios C, Saji S, Jung K, Hegg R . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase.... Lancet. 2020; 396(10257):1090-1100. DOI: 10.1016/S0140-6736(20)31953-X. View

14.

Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M . Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022; 33(5):534-543. DOI: 10.1016/j.annonc.2022.02.004. View

15.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

16.

Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y, Balassanian R . Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022; 33(8):814-823. DOI: 10.1016/j.annonc.2022.04.072. View

17.

Ohara A, Naoi Y, Shimazu K, Kagara N, Shimoda M, Tanei T . PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. Breast Cancer Res Treat. 2018; 173(3):533-543. DOI: 10.1007/s10549-018-5020-7. View

18.

Fujii T, Kogawa T, Dong W, Sahin A, Moulder S, Litton J . Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017; 28(10):2420-2428. PMC: 5834134. DOI: 10.1093/annonc/mdx397. View

19.

Landmann A, Farrugia D, Zhu L, Diego E, Johnson R, Soran A . Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?. Am J Clin Pathol. 2018; 150(1):34-42. DOI: 10.1093/ajcp/aqy028. View

20.

Dieci M, Griguolo G, Bottosso M, Tsvetkova V, Giorgi C, Vernaci G . Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer. 2021; 7(1):101. PMC: 8329161. DOI: 10.1038/s41523-021-00308-7. View